ASH 2018

Area: Hematology

Location: San Diego, United States

Date: December 1 to December 4

Description:

Annual Congress of the American Society of Hematology.


Search in Scientific Content:
Date
Filters:
Perioperat
7:20

Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: A Perioperative Management Plan for Patients with Atrial Fibrillation Who Are Receiving a Direct Oral Anticoagulant

Presenter: James Douketis
Hematology
Safety and
12:01

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

Presenter: Franco Locatelli
Hematology
A Randomiz
5:32

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Presenter: Tait D. Shanafelt
Hematology
Phase 3 Ra
6:37

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Presenter: Thierry Facon
Hematology
Acquisitio
5:45

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Presenter: Piers Blombery
Hematology
Best of AS
39:04

Best of ASH

Presenter: John D. Crispino
Hematology
Long Term
5:48

Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission

Presenter: Corinne Summers
Hematology
A Personal
6:14

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes

Presenter: Aziz Nazha
Hematology
Initial Re
6:41

Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies

Presenter: Amy Burd
Hematology
Multicente
8:43

Multicenter Microbiota Analysis Indicates That Pre-HCT Microbiota Injury Is Prevalent across Geography and Predicts Poor Overall Survival

Presenter: Jonathan U. Peled
Hematology
Rivaroxaba
11:08

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

Presenter: Alok A. Khorana
Hematology
Implementa
9:03

Implementation of a Sickle Cell Disease Screening Initiative in Uganda with HemoTypeSCTM

Presenter: Erik Serrao
Hematology
The Believ
7:26

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

Presenter: Maria Domenica Cappellini
Hematology
The Medali
6:49

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Presenter: Alan F. List
Hematology
Updated An
6:28

Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia

Presenter: Stephan A. Grupp
Hematology
Sustained
6:06

Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel

Presenter: Richard Thomas T. Maziarz
Hematology
Report on
7:29

Report on the European LeukemiaNet

Presenter: Ruediger Hehlmann
Hematology
Maximizing
3:21

Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial

Presenter: Charlotte Pawlyn
Hematology
Clinical a
3:24

Clinical advances in the field of myelodysplastic syndromes

Presenter: Eric Padron
Hematology
Pre-Treatm
4:59

Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi

Presenter: Michele Merli
Hematology
Novelties
4:28

Novelties on the treatment of acute myeloid leukaemia

Presenter: Adriano Venditti
Hematology
What is th
8:36

What is the recommended first-line treatment for patients with follicular lymphoma? Is "chemo-free" treatment an option?

Presenter: Kai Hübel
Hematology
Rivaroxaba
3:36

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

Presenter: Alok A. Khorana
Hematology

MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Presenter: John F. Seymour
Hematology
Chronic My
5:41

Chronic Myeloid Leukemia: With Great Success Comes Great Responsibility

Presenter: Charles Craddock
Hematology
Sustained
10:25

Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel

Presenter: Richard Thomas T. Maziarz
Hematology
CAR T-Cell
6:18

CAR T-Cell Therapies: New Research and Updates from Pivotal Trials

Presenter: Joseph Alvarnas
Hematology
Big Trials
4:33

Big Trials, Big Results: New and Novel Agents for the Treatment of Blood Diseases and Disorders

Presenter: David P. Steensma
Hematology
Ibrutinib
7:27

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL)

Presenter: Jennifer A. Woyach
Hematology
Excellent
3:21

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Presenter: Viola Poeschel
Hematology
Predictors
2:15

Predictors of Remission in Adults with Immune Thrombocytopenia Treated with Romiplostim

Presenter: Adrian Newland
Hematology
Novelties
6:05

Novelties in the treatment of chronic myeloid leukemia

Presenter: Giuseppe Saglio
Hematology

ISTH 2021

2021-07-17 - 2021-07-21
Online, Virtual

EHA 2021

2021-06-09 - 2021-06-17
Online, Virtual

ASH 2020

2020-12-05 - 2020-12-08
Online, Virtual

EHA 2020

2020-06-11 - 2020-06-21
Online, Virtual

ESH 2020

2020-05-29 - 2020-06-01
Online, Virtual

ASH 2019

2019-12-07 - 2019-12-10
Orlando, United States

EHA 2019

2019-06-13 - 2019-06-16
Amsterdam, Netherlands

EMMA 2019

2019-01-31 - 2019-02-02
Vienna, Austria

EHA 2018

2018-06-14 - 2018-06-17
Stockholm, Sweden